By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 12 November 2026
Tirzepatide is currently the most effective approved ingredient among the weight-loss injections – and the first to address two hormone systems at once. What a "dual agonist" means medically and how tirzepatide differs from semaglutide is covered on this page.
Tirzepatide activates the receptors of GLP-1 and GIP – two gut hormones that regulate satiety, appetite and fat metabolism. Pure GLP-1 injections (semaglutide, liraglutide) use only one of the two pathways. Because both act together, researchers call this the "twincretin" principle. The ingredient was developed by Eli Lilly and is marketed under the brand name Mounjaro (EU) or Zepbound (USA).
Linked original studies: SURMOUNT-1 and SURMOUNT-5 (NEJM).
Tirzepatide is injected once weekly. After a start-up phase at 2.5 mg, the dose usually rises to 5 mg and – depending on tolerability and target – further to 10 or 15 mg. Increments happen at intervals of at least four weeks to minimise nausea.
For users who prioritise maximum efficacy, tirzepatide is the first choice – the head-to-head data clearly sits on its side. But choosing the "right" injection also involves tolerability, pre-existing conditions, costs and personal preferences. Our injection comparison lines up all the options.
Yes. EU approval for weight management has existed since the end of 2023; in Germany the injection has been available since 2025 – for type 2 diabetes as well as the weight-loss indication.
Both are effective options. Direct comparisons show higher weight-loss rates for tirzepatide; tolerability, individual history and costs belong in the decision too – together with the medical team.
Once a week. There is no daily tirzepatide form.
Yes – the SURMOUNT trials were conducted in people without type 2 diabetes. The prerequisite for a prescription is a medically established indication (BMI ≥ 30 or ≥ 27 with a weight-related condition).